Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19)

The summary for the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19): The goal of the IPCAVD Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials. A preclinical research application alone is not sufficient for this announcement. Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the first 5 years of the award. The reduced support for two additional years will support ongoing stability studies, updating regulatory submissions and further optimization as informed from the clinical studies. However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. A clinical development plan describing means to initiate a clinical study during the first 5 years of award is a requirement of this FOA.
Federal Grant Title: Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-13-042
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.855
CFDA Descriptions: Allergy, Immunology and Transplantation Research
Current Application Deadline: Mar 13, 2015
Original Application Deadline: Mar 13, 2015
Posted Date: Dec 14, 2012
Creation Date: Dec 14, 2012
Archive Date: Apr 13, 2015
Total Program Funding: $4,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 C...
Center for HIV/AIDS Vaccine Immunology (CHAVI)
Genomics of Transplantation Cooperative Research Program
Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2019 FederalGrants.com